Technical and commercial development roadmap for Trojan DC cancer gene therapy
| Reference number | |
| Coordinator | Asgard Therapeutics AB |
| Funding from Vinnova | SEK 770 356 |
| Project duration | April 2020 - August 2021 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups step 2 spring 2020 |
Important results from the project
The aim of the project was to consolidate the technical and commercial strategies for Asgard Therapeutics in the development of a new cancer immunotherapy. We have achieved our goal by developing the manufacturing process for clinical quality materials; strengthening the position of intellectual property rights and gaining insights into financial requirements up to clinical development.
Expected long term effects
The project resulted in an updated business plan, with detailed strategic roadmap for the non-clinical and clinical activities, including financing requirements and time lines. It includes detailed analysis on the manufacturing strategy and CMC development objectives, as well as a revised IP strategy which resulted in filing of additional patent families. Regarding clinical trials, we have worked on the overall strategy and defining a clinical trial synopsis. All strategy input supported ongoing discussions with investors.
Approach and implementation
Asgard’s team has reviewed current manufacturing practices, engaged with CMOs and worked with a manufacturing consultant with expertise in gene therapies to perform a process mapping and gap analysis. We have also refined an IP strategy to secure protection of our technology and future developments, with the help of IP consultant. Finally, we have interacted with KOL in immune-oncology, potential pharma partners and US and European VC investors to define the roadmap for pre-clinical and clinical activities. We have also worked with a consultant for the clinical trial strategy.